PureTech Health plc (PTCHF)
USD 2.2
(0.0%)
USD 2.2
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -11.62 Million USD | 30.31% |
| 2022 | -52.18 Million USD | 5.67% |
| 2021 | -46.95 Million USD | -48.45% |
| 2020 | 62.68 Million USD | -52.62% |
| 2019 | 458.45 Million USD | 23.46% |
| 2018 | -65.26 Million USD | 10.63% |
| 2017 | -40.79 Million USD | -79.19% |
| 2016 | -74.8 Million USD | -70.54% |
| 2015 | -51.23 Million USD | -167.82% |
| 2014 | -73.23 Million USD | -552.7% |
| 2013 | -4.49 Million USD | 52.92% |
| 2012 | -9.67 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -32.29 Million USD | 0.0% |
| 2024 Q1 | -32.29 Million USD | 5.8% |
| 2023 Q2 | -73.1 Million USD | -100.0% |
| 2023 Q1 | -36.55 Million USD | 62.13% |
| 2023 FY | - USD | 30.31% |
| 2023 Q4 | -67.62 Million USD | -98.8% |
| 2023 Q3 | -34.01 Million USD | 53.47% |
| 2022 Q4 | -96.51 Million USD | -103.07% |
| 2022 Q2 | -96.89 Million USD | -100.0% |
| 2022 Q3 | -47.53 Million USD | 50.95% |
| 2022 FY | - USD | 5.67% |
| 2022 Q1 | -48.44 Million USD | 38.94% |
| 2021 FY | - USD | -48.45% |
| 2021 Q2 | -64.43 Million USD | -97.28% |
| 2021 Q4 | -79.34 Million USD | -96.85% |
| 2021 Q3 | -40.3 Million USD | 37.44% |
| 2021 Q1 | -32.65 Million USD | 47.44% |
| 2020 FY | - USD | -52.62% |
| 2020 Q2 | 88.35 Million USD | 447.65% |
| 2020 Q3 | -32.37 Million USD | -136.65% |
| 2020 Q4 | -62.14 Million USD | -91.92% |
| 2020 Q1 | -25.41 Million USD | 59.13% |
| 2019 FY | - USD | 23.46% |
| 2019 Q3 | -31.56 Million USD | 53.15% |
| 2019 Q4 | -62.17 Million USD | -96.98% |
| 2019 Q2 | -67.38 Million USD | -95.53% |
| 2019 Q1 | -34.46 Million USD | -38.11% |
| 2018 Q4 | -24.95 Million USD | 0.0% |
| 2018 FY | - USD | 10.63% |
| 2018 Q2 | -25.66 Million USD | 0.0% |
| 2018 Q1 | -25.66 Million USD | 10.15% |
| 2018 Q3 | -24.95 Million USD | 2.8% |
| 2017 Q3 | -28.56 Million USD | -2.86% |
| 2017 Q1 | -27.77 Million USD | -44.29% |
| 2017 Q2 | -27.77 Million USD | 0.0% |
| 2017 FY | - USD | -79.19% |
| 2017 Q4 | -28.56 Million USD | 0.0% |
| 2016 Q2 | -16.93 Million USD | 0.0% |
| 2016 FY | - USD | -70.54% |
| 2016 Q1 | -16.93 Million USD | -7.23% |
| 2016 Q4 | -19.24 Million USD | 0.0% |
| 2016 Q3 | -19.24 Million USD | -13.69% |
| 2015 Q3 | -15.78 Million USD | -178.89% |
| 2015 Q1 | -5.66 Million USD | 7.9% |
| 2015 FY | - USD | -167.82% |
| 2015 Q4 | -15.78 Million USD | 0.0% |
| 2015 Q2 | -5.66 Million USD | 0.0% |
| 2014 Q2 | -2.34 Million USD | 0.0% |
| 2014 Q4 | -6.14 Million USD | 0.0% |
| 2014 Q1 | -2.34 Million USD | 0.0% |
| 2014 FY | - USD | -552.7% |
| 2014 Q3 | -6.14 Million USD | -161.8% |
| 2013 FY | - USD | 52.92% |
| 2012 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 83.632% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | -96.107% |
| SQZ Biotechnologies Company | -64.14 Million USD | 81.873% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 33.063% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 112.364% |
| Mesoblast Limited | -62.38 Million USD | 81.364% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -656.942% |
| Genus plc | 73.7 Million USD | 115.776% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | -75.86% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | -227.798% |
| Marizyme, Inc. | -34.28 Million USD | 66.084% |
| ContraFect Corporation | -64.99 Million USD | 82.112% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | -32.547% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | -156.882% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -729.429% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | -339.676% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | -400.34% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -2144.395% |
| Accustem Sciences Inc. | -3.74 Million USD | -210.35% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 75.891% |
| EV Biologics, Inc. | -1.26 Million USD | -817.584% |
| Q BioMed Inc. | -617.62 Thousand USD | -1782.525% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 425.504% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -1738.534% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -408.954% |
| Biomind Labs Inc. | -1.03 Million USD | -1023.871% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 217.718% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | -62.359% |
| Skye Bioscience, Inc. | -13.54 Million USD | 14.176% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -681.693% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -46408.0% |
| Arch Therapeutics, Inc. | -3.88 Million USD | -199.332% |
| IMV Inc. | -35.52 Million USD | 67.269% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 26.735% |
| Curative Biotechnology, Inc. | -2.5 Million USD | -364.715% |
| GB Sciences, Inc. | -1.41 Million USD | -718.869% |
| Alpha Cognition Inc. | -9.7 Million USD | -19.797% |
| HST Global, Inc. | -5303.00 USD | -219153.253% |
| CSL Limited | 4.78 Billion USD | 100.243% |
| Halberd Corporation | -74.27 Thousand USD | -15553.146% |
| Enzolytics Inc. | -2.12 Million USD | -447.919% |
| Resverlogix Corp. | -11.74 Million USD | 0.979% |
| Affymax, Inc. | -14.29 Million USD | 18.664% |
| SYBLEU INC | -141.57 Thousand USD | -8112.84% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | -279.593% |
| argenx SE | -216.02 Million USD | 94.618% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 78.99% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 1055.382% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -675.699% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 3169.073% |
| AVAX Technologies, Inc. | -6.11 Million USD | -90.212% |
| Zenith Capital Corp. | -8.6 Million USD | -35.103% |
| Genscript Biotech Corporation | -248.71 Million USD | 95.325% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -66641.289% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | -375.258% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -6505.336% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 70.666% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | -301.995% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | -1011.236% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 173017.906% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | -564.4% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -505.286% |
| BioStem Technologies, Inc. | -7.55 Million USD | -53.926% |
| ONE Bio Corp. | 13.61 Million USD | 185.411% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -6320.635% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -465.241% |
| Agentix Corp. | -1.37 Million USD | -747.6% |
| LadRx Corporation | 412.28 Thousand USD | 2920.15% |
| Cell Source, Inc. | -4.27 Million USD | -172.134% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -3066.213% |
| Regen BioPharma, Inc. | 1.46 Million USD | 893.134% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -1140.943% |
| NovAccess Global Inc. | -1.03 Million USD | -1023.602% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 231.322% |
| Itoco Inc. | -1.86 Million USD | -522.099% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -2962.8% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -941.846% |
| Kadimastem Ltd | -2.62 Million USD | -343.038% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -4761.802% |
| CytoDyn Inc. | -18.02 Million USD | 35.509% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -14612.321% |
| Mobile Lads Corp. | -2.24 Million USD | -418.794% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -94977.275% |
| Qrons Inc. | -40.08 Thousand USD | -28908.757% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -2293.973% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 2304.451% |
| Rebus Holdings, Inc. | -951 Thousand USD | -1122.608% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -994.811% |
| International Stem Cell Corporation | 202 Thousand USD | 5855.941% |
| Bioxytran, Inc. | -3.82 Million USD | -204.36% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -21987.766% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | -372.271% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 67.585% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -25737.778% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | -324.653% |
| Neutra Corp. | -181.24 Thousand USD | -6315.003% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 42.324% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 42.32% |
| IXICO plc | -707 Thousand USD | -1544.554% |
| IntelGenx Technologies Corp. | -7.68 Million USD | -51.295% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 75.95% |
| CSL Limited | 4.73 Billion USD | 100.246% |
| Cellectis S.A. | -92.63 Million USD | 87.449% |